Studies have shown that GLP-1R agonists not only promote insulin secretion and exert glucose-lowering effects but also effectively delay gastric emptying, reduce intestinal motility, activate neural pathways in the hypothalamus and appetite regulation areas, resulting in decreased appetite and reduced food intake, thus treating obesity
Because Zepbound can sometimes lead to nausea or decreased fluid intake, the risk of dehydration increases
When this cardiometabolic benefit slide was shown there was audible murmuring and comments
Onset of effects is usually in the range of 30 to 60 minutes post-injection, with peak effects around 1 hour and lasting a few hours in terms of plasma half-life
Unfortunately, due to an insurance change, I needed to go off the GLP-1 drug I was taking, and over several months, I watched my total daily insulin needs climb steadily
The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms